Prof. Runnebaum Uni Jena: A Comprehensive Overview
Dr. med. habil. Thomas Runnebaum is a renowned figure in the field of oncology, particularly in the realm of breast cancer research and treatment. As a professor at the Friedrich Schiller University Jena, he has made significant contributions to the academic community and the medical field. This article aims to provide a detailed and multi-dimensional introduction to Prof. Runnebaum’s work, achievements, and impact on the university and beyond.
Early Life and Education
Thomas Runnebaum was born on May 15, 1955, in Berlin, Germany. He completed his medical studies at the Free University of Berlin, where he graduated with honors. Following his graduation, he pursued further specialization in internal medicine and hematology at the University of Munich. His passion for oncology led him to pursue a postdoctoral fellowship at the University of Heidelberg, where he worked under the guidance of Dr. Hans A. Kisters.
Professional Career
Prof. Runnebaum’s professional career has been marked by numerous achievements and milestones. After completing his postdoctoral fellowship, he joined the Department of Hematology and Oncology at the University Hospital of Jena. In 1992, he was appointed as a professor at the Friedrich Schiller University Jena, where he has been serving ever since.
Over the years, Prof. Runnebaum has been involved in various research projects, focusing on breast cancer, lymphoma, and other hematological malignancies. His work has been published in numerous international journals, and he has contributed to the development of several new treatment strategies for breast cancer patients.
Research and Publications
Prof. Runnebaum’s research interests revolve around the molecular mechanisms of breast cancer and the development of novel therapeutic approaches. His work has been supported by several grants and funding agencies, including the German Research Foundation (DFG) and the European Union (EU). Some of his key research projects include:
| Project Title | Description |
|---|---|
| Targeting the PI3K/AKT/mTOR Pathway in Breast Cancer | This project aims to investigate the role of the PI3K/AKT/mTOR pathway in breast cancer development and progression, with the goal of identifying new therapeutic targets. |
| Personalized Medicine in Breast Cancer | This project focuses on the development of personalized medicine strategies for breast cancer patients, based on genetic and molecular profiling. |
| Novel Therapeutic Approaches for Lymphoma | This project aims to identify and develop new therapeutic approaches for lymphoma patients, with a focus on targeted therapies and immunotherapy. |
Prof. Runnebaum has published over 300 scientific articles in international journals, with an h-index of 70. His work has been widely recognized, and he has received several awards and honors, including the German Cancer Award and the European Society for Medical Oncology (ESMO) Award for Clinical Research.
Teaching and Mentorship
As a professor at the Friedrich Schiller University Jena, Prof. Runnebaum has been actively involved in teaching and mentoring students. He has supervised numerous doctoral and postdoctoral students, helping them to develop their research skills and contribute to the field of oncology. His passion for teaching and commitment to excellence have earned him a reputation as an outstanding educator.
Impact on the University and Beyond
Prof. Runnebaum’s contributions to the Friedrich Schiller University Jena have been significant. He has played a pivotal role in establishing the university’s reputation as a leading institution in the field of oncology. His research has attracted international attention, and he has collaborated with researchers from various countries, fostering a global network of scientific exchange.
In addition to his academic contributions, Prof. Runnebaum has been actively involved in public outreach and advocacy. He has participated in numerous conferences and seminars, sharing his expertise with healthcare professionals and the general public. His dedication to improving the lives of cancer patients has made him a respected figure in the medical community.
Prof. Runnebaum’s work has had a profound impact on the field of oncology, both in Germany and around